Can Biopsy Spread Cancer?
No, biopsy does not meaningfully spread cancer in clinical practice, and the benefits of accurate diagnosis far outweigh the extremely rare theoretical risk of needle-tract seeding.
The Evidence on Needle-Tract Seeding
The concern about biopsies spreading cancer stems from rare case reports of "needle-tract seeding," but this phenomenon is extraordinarily uncommon:
In prostate cancer, the incidence of needle-tract seeding is <1% across all reported cases 1. Despite the dramatic increase in prostate biopsies performed over decades, the number of reported seeding cases has not increased proportionally 1.
In liver lesions, patients with hepatocellular carcinoma (HCC) have a needle-track seeding rate of only 0.1% to 0.7% 2.
In lung cancer, preoperative biopsy (both percutaneous and bronchoscopic) showed no significant association with tumor spread through airspaces (STAS) or worse outcomes in stage I non-small cell lung cancer 3. The study of 2,169 patients found that preoperative biopsy was not a risk factor for recurrence or mortality 3.
Why Biopsy Is Essential Despite Theoretical Risks
The diagnostic and therapeutic benefits of biopsy vastly outweigh any minimal seeding risk 1. Here's why biopsy remains the standard of care:
Diagnostic Necessity
- Biopsy provides definitive histopathologic diagnosis, which is essential for treatment planning 4, 2
- For certain cancers like lymphoma, histopathologic analysis is the only technique that can make a definitive diagnosis 2
- Molecular and biomarker testing from biopsy tissue guides targeted therapy selection 5, 6
Clinical Context Matters
The guidelines frame biopsy appropriately based on clinical scenarios 4:
- For suspicious lesions (e.g., persistent ground-glass nodules), percutaneous lung biopsy is rated as "usually appropriate" (rating 7/9) 4
- Image-guided liver biopsies achieve 91% positivity in patients with known primary malignancy, with only 6% nondiagnostic 2
Important Caveats and Nuances
When Seeding Has Been Observed
The rare cases of needle-tract seeding have certain patterns:
- More commonly reported after transperineal prostate biopsy than transrectal approach 1
- In breast cancer, a 2025 study found tumor extension through biopsy tracts in 3 of 62 patients (4.8%), primarily in larger tumors (average 3.9 cm) with luminal subtypes 7
The Circulating Tumor Cell Question
One study found that prostate biopsies can release circulating tumor cells (CTCs) into the bloodstream 8. However, the presence of CTCs does not equate to metastatic spread—cancer cells must successfully implant, survive, and grow at distant sites, which is an inefficient process that rarely occurs from biopsy alone.
Real Procedural Risks to Discuss
The actual risks patients face from biopsies are:
- Pneumothorax and bleeding from lung biopsies 4
- Postbiopsy bleeding (9-12% with hypervascular liver lesions) 2
- Infection risk from prostate biopsies 1
These complications are far more common and clinically relevant than needle-tract seeding.
Clinical Bottom Line
Appropriate counseling should acknowledge the theoretical possibility of seeding while emphasizing that it is extraordinarily rare and does not change clinical recommendations 1. The benefits of accurate cancer diagnosis and appropriate management categorically outweigh any potential seeding risks 1. Avoiding biopsy due to seeding concerns would result in far worse outcomes—missed diagnoses, delayed treatment, and inability to select optimal targeted therapies.